Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Claggett

Showing results (201-210 of 361) with videos related to

Pageof 37
Sort By:
European Journal of Heart Failure|April 30, 2021
Left atrial structure and function of the amyloidogenic V122I transthyretin variant in elderly African AmericansMasatoshi Minamisawa, Riccardo M Inciardi, Brian Claggett, et al.
Journal of the American College of Cardiology|October 4, 2014
Reply: does speckle tracking really improve diagnosis and risk stratification in patients with HF with normal EF?Amil M Shah, Elisabeth Kraigher-Krainer, Deepak K Gupta, et al.
Circulation. Heart Failure|August 4, 2022
Timing of Statistical Benefit of Mineralocorticoid Receptor Antagonists Among Patients With Heart Failure and Post-Myocardial InfarctionWassim Bedrouni, Abhinav Sharma, Bertram Pitt, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|March 14, 2020
Association of post-diagnosis cardiorespiratory fitness with cause-specific mortality in cancerJohn D Groarke, David L Payne, Brian Claggett, et al.
Diabetes, Obesity & Metabolism|August 14, 2023
Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trialsHiddo J L Heerspink, Priya Vart, Niels Jongs, et al.
ESC Heart Failure|March 12, 2021
Sex differences in congestive markers in patients hospitalized for acute heart failureCaroline Espersen, Ross T Campbell, Brian Claggett, et al.
Diabetes, Obesity & Metabolism|December 22, 2022
Effect of lixisenatide on natriuretic peptides in people with type 2 diabetes and recent acute coronary syndrome: The ELIXA trialHertzel C Gerstein, Emil Wolsk, Brian Claggett, et al.
Kidney360|May 7, 2025
Association of Different Definitions of Erythropoiesis-Stimulating Agent Hyporesponsiveness with Major Adverse Cardiovascular Events: Insights From ASCEND-DFinnian R Mc Causland, Sushrut S Waikar, Brian Claggett, et al.
Circulation. Heart Failure|February 27, 2016
Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) TrialScott D Solomon, Brian Claggett, Akshay S Desai, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|October 10, 2019
Catheter ablation for atrial fibrillation is associated with lower incidence of heart failure and deathDaniel Modin, Brian Claggett, Gunnar Gislason, et al.
Pageof 37

Showing results (201-210 of 361) with videos related to

Sort By:
Pageof 37
European Journal of Heart Failure|April 30, 2021
Left atrial structure and function of the amyloidogenic V122I transthyretin variant in elderly African AmericansMasatoshi Minamisawa, Riccardo M Inciardi, Brian Claggett, et al.
Journal of the American College of Cardiology|October 4, 2014
Reply: does speckle tracking really improve diagnosis and risk stratification in patients with HF with normal EF?Amil M Shah, Elisabeth Kraigher-Krainer, Deepak K Gupta, et al.
Circulation. Heart Failure|August 4, 2022
Timing of Statistical Benefit of Mineralocorticoid Receptor Antagonists Among Patients With Heart Failure and Post-Myocardial InfarctionWassim Bedrouni, Abhinav Sharma, Bertram Pitt, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|March 14, 2020
Association of post-diagnosis cardiorespiratory fitness with cause-specific mortality in cancerJohn D Groarke, David L Payne, Brian Claggett, et al.
Diabetes, Obesity & Metabolism|August 14, 2023
Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trialsHiddo J L Heerspink, Priya Vart, Niels Jongs, et al.
ESC Heart Failure|March 12, 2021
Sex differences in congestive markers in patients hospitalized for acute heart failureCaroline Espersen, Ross T Campbell, Brian Claggett, et al.
Diabetes, Obesity & Metabolism|December 22, 2022
Effect of lixisenatide on natriuretic peptides in people with type 2 diabetes and recent acute coronary syndrome: The ELIXA trialHertzel C Gerstein, Emil Wolsk, Brian Claggett, et al.
Kidney360|May 7, 2025
Association of Different Definitions of Erythropoiesis-Stimulating Agent Hyporesponsiveness with Major Adverse Cardiovascular Events: Insights From ASCEND-DFinnian R Mc Causland, Sushrut S Waikar, Brian Claggett, et al.
Circulation. Heart Failure|February 27, 2016
Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) TrialScott D Solomon, Brian Claggett, Akshay S Desai, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|October 10, 2019
Catheter ablation for atrial fibrillation is associated with lower incidence of heart failure and deathDaniel Modin, Brian Claggett, Gunnar Gislason, et al.
Pageof 37